National NewsUSA News

Pfizer and BioNTech target healthy children ages 5-11 for COVID Booster

Pfizer and BioNTech announced Thursday that they would seek approval to issue coronavirus boosters to healthy elementary-aged children up to age five.

The push comes on the heels of a small-scale study providing new data showing that healthy children aged five to 11 could benefit from another child-sized vaccine. The data has not been published or verified by independent experts, AP reports.

“Pfizer and BioNTech plan to submit an Emergency Use Authorization (EUA) request for a booster dose for children ages 5-11 in the United States in the coming days,” the companies said. in a press release.

US health officials are already urging everyone 12 and older to receive a booster dose to protect against the new variants, while the option of a second booster for those 50 and older is already available.

As Breitbart News reported, last year the companies said they were preparing to seek permission to vaccinate children five and older as the company stood ready to start manufacturing doses. lower for children under 12. It has now materialized.

According to the AP report, Pfizer shots are the only vaccine available for American children. People 5 to 11 years old get one-third the dose given to everyone 12 years and older. Just over a quarter of young people have received two doses since the vaccination was opened to them in November, shortly before the arrival of omicron.

The United States has not yet authorized the vaccination of children under the age of five. But some children aged 5 to 11 – those with severely weakened immune systems – are already supposed to receive three doses, to give this high-risk group a better chance of responding.

Meanwhile, Moderna has released “positive interim data” from trials of just two doses of its vaccine in children as young as six months old, with the intention of seeking FDA clearance in the coming weeks.

Follow Simon Kent on Twitter: or by e-mail to: [email protected]


Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.
Back to top button